Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up

Zinc oxide vs MEBO for stage 2 pressure ulcers

Official title: Impact of Using Zinc Oxide Versus Moist Exposed Wound Ointment (MEBO) in Treatment of Second Stage Pressure Ulcer: A Randomized Control Clinical Trial

Run by King Abdullah Medical City · NCT07193849 · Data updated 2026-11-12

This trial tests whether applying zinc oxide or MEBO ointment heals stage 2 pressure ulcers faster in hospitalized patients.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment76 (estimated)
SponsorKing Abdullah Medical City
Government
Drugs / interventionschemotherapy, radiation
Locations2 sites (Mecca, Western Reagan and 1 other locations)
StatusRecruiting
StartedDecember 31, 2023
Main results expectedDecember 31, 2025
Study endsDecember 31, 2025
Registry record updatedSeptember 26, 2025
Trial IDNCT07193849 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Hospitalized patients at King Abdullah Medical City with newly diagnosed stage 2 pressure ulcers who consent and are not receiving therapies that interfere with wound healing are eligible.

Probably not a fit

Patients with stage III/IV ulcers, deep tissue injury, signs of wound infection, hypersensitivity to the ointments, active cancer therapies, or heavy smoking are excluded and unlikely to benefit from these interventions.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with newly diagnosed stage 2 pressure ulcers at King Abdullah Medical City are randomized 1:1 to receive either topical zinc oxide or MEBO ointment. Treatments are applied twice every 12 hours and patients are examined daily until complete healing or for up to one month. Wound healing is measured using the Bates-Jensen Wound Assessment Tool and data are recorded on a standardized assessment sheet. Randomization is performed electronically in R using the Random Allocation Rule.

Why it matters

Potential benefit: If successful, one ointment could speed healing of stage 2 pressure ulcers and reduce complications and length of stay.

How similar studies have gone: Topical zinc formulations and moist-exposed ointments have shown wound-healing benefits in other settings, but direct head-to-head comparisons for stage 2 pressure ulcers are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Willing to participate.
* KAMC cases in medical ward, neuroscience ward, and intensive care unit.
* Newly cases diagnosed with second stage pressure ulcer according to the European pressure ulcer advisory panel/national pressure ulcer advisory panel (NPUAP) guidelines.

Exclusion Criteria:

* Not consenting to participate
* Patients with suspected hypersensitivity reactions to any of the topical formulation's ingredients.
* Either a category III or IV pressure ulcer.
* Evidence of deep tissue injury (exudative drainage, purple or maroon localized area of discolored intact skin or blood-filled blister due to pressure damage).
* Signs of wound infection (pus draining from the ulcer, a foul-smelling odour, tenderness, heat and increased redness in the surrounding skin and fever).
* Patients who undertaking other therapies that could affect healing, such as corticosteroids, radiation therapy, or chemotherapy for cancer.
* Heavy smoking (more than 20 cigarettes a day).
* Concomitant chronic disease (e.g., diabetes mellitus or frank vascular disease such as Buerger's disease).
* Patients who unable to continue the study because of death, discharge, or change in the care setting.

Where it's running

  • King Abdulla Medical City in Holy capital
    Mecca, Western Reagan, Saudi Arabia
    Recruiting
  • King Abdulla Medical City in Holy capital
    Mecca, Western Reagan, Saudi Arabia
    Completed

Study contacts

  • Principal investigator: Dr. Ebtisam AbdElatif Ebrahim, Master degree of science in nu — King Abdullah Medical City in Holy Capital
  • Study coordinator: wedian Almowallad, Master
  • Email: Almwlld.W@kamc.med.sa
  • Phone: +96612 5549999

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.